Skip to main content
  • Original article
  • Open access
  • Published:

Serum adiponectin as a biomarker for chronic obstructive pulmonary disease and lung cancer and its relation to severity

Abstract

Introduction

‘Chronic obstructive pulmonary disease’ (COPD) is an inflammatory disorder associated with airway narrowing and airflow limitation in response to air pollution, gases, and smoking and is associated with morbidity and mortality. Cancer is also considered as a systemic inflammatory disorder where pro-inflammatory cytokines and mediators are released.

Aim

To evaluate serum adiponectin level in COPD and lung cancer and its importance in detecting and predicting severity.

Patients and methods

A total of 40 patients were recruited in the study: 20 had stable COPD and 20 had lung cancer. Moreover, another 10 age-matched and sex-matched individuals were included as a control group. All were subjected to routine laboratory chest radiography, spirometry, and serum adiponectin level measurement.

Results

The results showed an increase of adiponectin level in both patients with COPD and those with lung cancer, and significant correlation was found between adiponectin level and forced expiratory volume in 1 s and performance status.

Conclusion

Adiponectin serum level is elevated in both COPD and lung cancer and significantly elevated in severe cases.

References

  1. Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global strategy for the diagnosis management and prevention of chronic obstructive pulmonary disease imported , 2014.

  2. Barues PJ, Celli BR. Systemic manifestations and comorbidities of COPD. Eur Respir J 2009;33:1165–1185.

    Article  Google Scholar 

  3. Nishimura M, Makita H, Nagaik K, Nasuhara Y, Hasegawa M, Shimizu K, et al. Hokkaido COPD Cohort Study Investigators. Annual change in pulmonary function and clinical phenotype in chronic obstructive pulmonary disease. Am J Respir Critcare Med 2012;185:44–52.

    Article  Google Scholar 

  4. Park HY, Churg A, Wright JL, Tam S, Man SF, Tashkin D, et al. Club cell protein 15 and disease progression in COPD. Am J Respir Crit Care Med 2013;188:1413–1419.

    Article  CAS  Google Scholar 

  5. Sato M, Shibata Y, Abe I, Igarashi A. Retrospective analysis of the relationship between decline in FEV1 and abdominal circumference in male smokers:The Takahata study. Int J Med SCi 2013;10:1–7.

    Article  Google Scholar 

  6. MatsuZawa Y, Funahashi T, Kihara S, Shimomural I. Adiponectin and metabolic syndrome. Anterioxler Thromb Vasc Biol 2004;24:29–33.

    Article  CAS  Google Scholar 

  7. Tomoda K, Yoshi Kaw AM, Tamaki TT. Fulcuo KaA:elevated circulating plasma adiponectin inunderweight pts. withCOPD. Chest 2007;132:135–140.

    Article  CAS  Google Scholar 

  8. Woschki B, Kirsten A, Holzo L, Muller KC, Meyer T. Physical activity is the strongest predictor of all-cause mortality in patients with COPD:a prospective Cohort study. Chest 2011;140:331–342.

    Article  Google Scholar 

  9. Yoon HI, Liy Man SF, Tashkin D, Wise RA. The complex relationship of serum adiponectin to COPD outcomes COPD and adiponectin. Chest 2012;142:893–899.

    Article  CAS  Google Scholar 

  10. Meier U, Gressner A. Endocrine regulation of energy metabolism:review of pathobiochemical and clinical aspects of leptin, ghrelin, adiponectin and resist in. Clin Chem 2004;50:1511–1525.

    Article  CAS  Google Scholar 

  11. Deans C, Wigmor SJ. Systemic inflammation, cachexia and prognosis in patients with cancer. Curr Opin Clin Nutr Metab Care 2005;8:265–269.

    Article  CAS  Google Scholar 

  12. Sharma D, Wang J, Fu PP, Sharma S. Adiponectin shows potential in blocking obesity-related carcinogenesis. Sci Daily 2005;24:230–234.

    Google Scholar 

  13. Pauwels RA, Buist AS, Calverley PM, Jenkin’s CR, Hurd SS. Global strategy for chronic obstructive pulmonary disease disease NHLB1 who global initiative for chronic obstructive pulmonary disease (GOLD) workshop summary. Am J Respir Crit Care Med 2001;163:1256–1276.

    Article  CAS  Google Scholar 

  14. Chamberlain N, Driver E, Miesfeld R. The length and location of CAG trinucleotide repeats in the androgen receptor N-terminal domain affect transactivation function. Nucleic Acids Res 1994;22:3181–3186.

    Article  CAS  Google Scholar 

  15. De Haan R, Aaronson A. Measuring quality of life in stroke. Stroke 1993;24:320–327.

    Article  Google Scholar 

  16. Aprahamian TR, Sam F. Adiponectin in cardiovascular inflammation and obesity. Int J inflame 2011; 2011:376909.

    Google Scholar 

  17. Pauwels RA, Buist AS, Calverley PM, Jemkins CR, Hurdss A. Global strategy for the diagnosis management and prevention of COPD. Am J Respir Cril Care Med 2001;163:1256–1276.

    Article  CAS  Google Scholar 

  18. Krommidas G, Kostikas K, Paptheodorou G. Plasma leptin and adiponectin in COPD exacerbation. Respir Med 2009; 1978:2551.

    Google Scholar 

  19. Kirdar S, Serter M, Ceylan E, Sener AG, Kalvak T, Karadag F. Adiponectin as a biomarker of systemic inflammatory response in swster parieuts with stable and exacerbation phases chronic obstructive pulmonary disease. Scand J Clin Lab Invest 2009;69:219–224.

    Article  CAS  Google Scholar 

  20. Sato K, Shibata Y, Abe S, Inoue S. Association between plasma adiponectin levels and decline in forced expiratory volume in 1st second in a general Japanese population:the Takahata study. Int J Med Sci 2014;11:758–765.

    Article  Google Scholar 

  21. Bruno A, Chanez P, Chiappara G, Sienal H, Mancos G. Does leptin play a cytokine-like role within the airways of COPD patients? Eur Respir J 2005;26:398–405.

    Article  CAS  Google Scholar 

  22. Chong IW, Liu PL, Tsai JR, Wang TH, Hwang JJ, Kaohsiung TW. Over expression of adiponectin gene can enhance cancer cell metastatic ability in non-small cell lung cancer. Am J Respir Crit Care Med 2011;183:5120–5124.

    Google Scholar 

  23. Wazj Cheng YJ, Gawj Aung LH. Adiponectin is associated with increased mortality in patients with already established cardiovascular disease:a systemic review and meta-analysis. Metabolism 2014;63:1157–1166.

    Article  Google Scholar 

  24. Perrier S, Jarde T. Adiponectin an anti-carcinogenic hormone? A systematic review on breast, colorectal, liver, and prostate cancer. Curr Med Chem 2012;19:5501–5512.

    Article  CAS  Google Scholar 

  25. Wang SN, Yang SF, Tsai HH, Leek T, Yeh YT. Increased adiponectin associated with poor survival in hepatocellular carcinoma. J Gastroenterol 2014;49:1342–1351.

    Article  Google Scholar 

  26. Howard JM, Cath Cart MC, Healy L, Beddy P. Leptin and adiponectin receptor expression in oesophageal cancer. Br J Surg 2014;101:643–652.

    Article  CAS  Google Scholar 

  27. Singh N, Aggarwal AN, Gupta D, Behera D. Prevalence of low body mass index among newly diagnosed lung cancer patients in North India and its association with smoking status. Thorac Cancer 2011;2:27–31.

    Article  Google Scholar 

  28. Scott HR, McMillan DC, Brown DJ, Forrest LM, McArdle CS, Milroy R. A prospective study of the impact of weight loss and the systemic inflammatory response on quality of life in patients with inoperable non-small cell lung cancer. Lung Cancer 2003;40:295–299.

    Article  Google Scholar 

  29. Barb D, Pazaitou-Anayiotou K, Mantzoros CS. Adiponectin:a link between obesity and cancer. Expert Opin Investig Drugs 2006;15:917–931.

    Article  CAS  Google Scholar 

  30. Serter M, Kirdar S, Ceylan E, Kavak T, Gültekin B. The value of adiponectin as an inflammatory marker in lung cancer? Eur Res J 2010;277:777–780.

    Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Riham H. Raafat MD.

Additional information

This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.

Rights and permissions

This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Gayed, A.T., Raafat, R.H. Serum adiponectin as a biomarker for chronic obstructive pulmonary disease and lung cancer and its relation to severity. Egypt J Bronchol 12, 386–390 (2018). https://doi.org/10.4103/ejb.ejb_22_18

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.4103/ejb.ejb_22_18

Keywords